Summit Therapeutics Overview
Summit Therapeutics (SMMT) has a P/E ratio of -15.94, below the sector sector average of 35.6.
Get informed when a big investor buys or sells
+ Follow-15.94
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, SMMT shows a P/E ratio of -15.94. That is below the sector sector average of 35.6. Scroll down for historical charts and peer comparison views.
The its sector sector average P/E ratio is about 35.6. Summit Therapeutics is at -15.94, which is lower that average. That is roughly 144.8% below the sector mean. Use the comparison chart on this page to see how SMMT stacks up against individual peers as well.
Investors watch SMMT's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Summit Therapeutics's latest reading is -15.94. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has Summit Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently -15.94) with ownership activity and broader fundamentals.
